DS
CADL icon

David Shaw’s Candel Therapeutics CADL Stock Holding History

David Shaw’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.12M Buy
+108,933
New +$823K ﹤0.01% 3675
2022
Q2 		– Sell
-10,867
Closed -$55K – 5360
2022
Q1 		$55K Buy
10,867
+745
+7% +$3.7K ﹤0.01% 5123
2021
Q4 		$79K Buy
+10,122
New +$98.3K ﹤0.01% 5117

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

David Shaw's CADL Position: Q2 2026 in Review

David Shaw opened a new position in Candel Therapeutics (CADL) in Q2 2026: 108,933 shares worth $1.12M. The stake represents ﹤0.01% of the portfolio and ranks #3675 among its holdings. This is a return to the name: David Shaw previously reported a position in CADL as recently as Q1 2022.

David Shaw first reported a position in CADL in Q4 2021 and has held it in 3 quarters since. 137 funds tracked by Wall St. Rank hold CADL as of Q2 2026.

  • David Shaw held 108,933 shares of Candel Therapeutics worth $1.12M as of Q2 2026.
  • Candel Therapeutics was a new David Shaw position in Q2 2026.
  • Candel Therapeutics made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #3675 holding.
  • David Shaw first reported a position in Candel Therapeutics in Q4 2021 and has held it in 3 quarters since.
  • 137 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.